In anemia management for dialysis patients, what is the typical approach?

• A. Erythropoiesis-stimulating agents and iron; transfusion only for symptomatic anemia
• B. Routine transfusions for all patients
• C. Only iron supplements with no ESA
• D. ESA without iron

Answer: (A)

Managing anemia in dialysis patients focuses on using erythropoiesis-stimulating agents to stimulate red blood cell production while ensuring there is enough iron available for hemoglobin synthesis, with transfusions reserved for symptomatic cases or when rapid correction is needed. ESAs address the deficiency in erythropoietin, but they can only work if iron stores are sufficient; iron is often given IV during dialysis to optimize the response. Transfusions carry risks such as immune reactions, infections, and fluid overload, so they’re not used routinely for every patient. Without iron, ESA therapy is often ineffective, and giving iron without an ESA won’t raise hemoglobin if erythropoiesis isn’t being stimulated.